?(Fig.1B).1B). patient is still alive in excellent condition with sustained tumor response. Conclusion In summary, we report on a very rare case BNP (1-32), human of a patient with HCC demonstrating an almost complete response to checkpoint inhibitor treatment. strong class=”kwd-title” Keywords: Hepatocellular carcinoma, Nivolumab, PD-L1, Response Introduction Hepatocellular carcinoma (HCC) represents the most common primary malignancy of the liver. In almost BNP (1-32), human all cases HCC occurs in the setting of chronic liver injury and liver cirrhosis. In the last decade, HCC has risen to become the fifth most common cause of cancer and the second leading cause of cancer-related death worldwide [1]. The incidence of HCC varies from 3/100,000 in Western countries to 78/100,000 in Africa and Asia, mapping the geographical distribution of its most important risk factors, i.e., viral hepatitis B (HBV) and hepatitis C (HCV) [2, 3]. Besides viral hepatitis and alcoholic liver disease, metabolic diseases such as diabetes mellitus type 2 and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis have emerged as risk factors that are increasingly prevalent, especially in the Western world [4]. Therapeutic management of HCC is dependent on the extent of the tumor and the BNP (1-32), human degree of liver dysfunction. While in patients with early tumor stages, surgical resection, orthotopic liver transplantation, or ablative therapies might offer the chance for cure, approximately 50% of patients are diagnosed with locally advanced or metastatic disease and, therefore, are not eligible for these potentially curative treatments [2, 3] but should receive systemic therapy. Based on the results of the SHARP study, sorafenib was established for almost a decade as the sole systemic treatment for these patients [5]. However, in clinical routine, sorafenib is associated with significant toxicities such as hand-foot syndrome, fatigue, and gastrointestinal side effects. Only recently, lenvatinib was introduced as an alternative first-line treatment option in the context of advanced or metastasized HCC. After failure of a first-line therapy, regorafenib and, in the case of patients with a baseline alpha-fetoprotein (AFP) 400 ng/mL, ramucirumab have demonstrated efficacy in the RESOURCE and REACH-2 trials, respectively [6]. In recent years, immunotherapy in the form of immune checkpoint blockade has initiated a paradigm shift in cancer treatment [7]. Blockade of immune checkpoint pathways such as BNP (1-32), human the programmed cell death receptor-1 (PD-1) pathway or the cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway can potentially offer a treatment strategy to reinstate host immune response against HCC and ultimately tumor regression [8]. Just recently, both the CheckMate 040 trial and the KEYNOTE-224 trial, large single-arm phase I/II trials, have reported promising results for nivolumab and pembrolizumab when used as salvage therapy after failure of a sorafenib-based first-line therapy in patients with advanced or metastatic HCC [9, 10]. In both trials, fatigue, pruritus, and rash embodied the most prevalent adverse events. Notably, the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface was not found to be predictive for treatment response or patients survival. We report a case of a patient with HCC that demonstrated an excellent response to treatment with nivolumab after being intolerant to a first-line therapy with sorafenib. Case Report We Rabbit Polyclonal to KLF10/11 report the case of a 77-year-old female patient with BNP (1-32), human chronic HCV-associated liver cirrhosis. Chronic HCV infection (genotype 1b) was first diagnosed as non-A, non-B hepatitis in 1995, and the patient was later treated with pegylated interferon-2a in combination with ribavirin, but did achieve a sustained virological response. A DAA treatment had yet not been initiated for unknown reason..